Table 5.

Number and proportion of patients with AEs^a by each study period (safety population)

Study Period	Treatment Arm
	Placebo (n = 21)	Fermagate 1 g (n = 21)	Fermagate 2g (n = 21)	Total (n = 63)
Screening	0 (0.0)	1 (4.8%)	3 (14.3%)	4 (6.3%)
Current therapy	8 (38.1%)	10 (47.6%)	9 (42.9%)	27 (42.9%)
Washout	8 (38.1%)	9 (42.9%)	10 (47.6%)	27 (42.9%)
Study treatment	15 (71.4%)	13 (61.9%)	20 (95.2%)	48 (76.2%)
Follow-up	1 (4.8%)	4 (19.0%)	1 (4.8%)	6 (9.5%)

^aAEs, adverse events.